Global Pemphigus Vulgaris Market 2022 - Snapshot

August 2022 | 47 pages | ID: GE991148F750EN
Gen Consulting Company

Abstracts

According to latest analysis by Gen Consulting Company, the global pemphigus vulgaris market is poised to grow by USD 184 million during 2022-2028, progressing at a CAGR of 7.1% during the forecast period.

This industry report offers market estimates of the global market, followed by a detailed analysis of the treatment type, route of administration, end user, and region. The global market data on pemphigus vulgaris can be segmented by treatment type: biological therapies, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIG), others. Pemphigus vulgaris market is further segmented by route of administration: intravenous, oral, subcutaneous. Based on end user, the pemphigus vulgaris market is segmented into: academic & research institutes, hospitals, specialty dermatology clinics. On the basis of region, the pemphigus vulgaris market also can be divided into: North America, Asia Pacific, Europe, Rest of the World (ROW).

The global pemphigus vulgaris market is highly competitive. Key companies profiled in the report include Almirall S.A., argenx SE, Biogen Inc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., Principia Biopharma Inc., Sanofi S.A., Syntimmune Inc.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

• Get a detailed picture of the Global Pemphigus Vulgaris Market
• Identify segments/areas to invest in over the forecast period in the Global Pemphigus Vulgaris Market
• Understand the competitive environment, the market’s leading players
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. SUMMARY

PART 2. INTRODUCTION

Study period
Geographical scope
Market segmentation

PART 3. PEMPHIGUS VULGARIS MARKET OVERVIEW

PART 4. MARKET BREAKDOWN BY TREATMENT TYPE

Biological therapies
Corticosteroids
Immunosuppressants
Intravenous immunoglobulin (IVIG)
Others

PART 5. MARKET BREAKDOWN BY ROUTE OF ADMINISTRATION

Intravenous
Oral
Subcutaneous

PART 6. MARKET BREAKDOWN BY END USER

Academic & research institutes
Hospitals
Specialty dermatology clinics

PART 7. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 8. KEY COMPANIES

Almirall, S.A.
argenx SE
Biogen Inc.
F. Hoffmann-La Roche AG
Novartis AG
Pfizer Inc.
Principia Biopharma Inc.
Sanofi S.A.
Syntimmune Inc.

PART 9. METHODOLOGY